Resumen

GARCIA-ROBLEDO, Juan Esteban  y  GARCIA-PERDOMO, Herney Andrés. Checkpoint inhibition: the current treatment of renal cell carcinoma. Rev. mex. urol. [online]. 2022, vol.82, n.2, e06.  Epub 20-Feb-2023. ISSN 2007-4085.  https://doi.org/10.48193/revistamexicanadeurologa.v82i2.839.

Immune surveillance is one of the most important hallmarks of cancer. In the last decade many advancements in cancer treatment have been developed, much of them are related to the use of the immune system. Renal Cell Carcinoma is the most frequent type of kidney cancer followed by urothelial carcinoma. For years, treatment of Renal Cell Carcinoma has been conflictive as these tumors do not respond well to chemotherapy and have shown to be susceptible to immunotherapies as interferon and interleukin 2. The discovery of the immune checkpoints and their possible roles in cancer treatment led to the synthesis of novel drugs that can target and inhibit the interaction of certain molecules that are important for immunologic homeostasis. In this concise review, we summarize the evidence related with immune checkpoint inhibition for the treatment of renal cell carcinoma, especially for metastatic renal cell carcinoma.

Palabras llave : immunotherapy; renal cell carcinoma; immune checkpoint; overall survival.